Overview

* RenovoRx ( RNXT ) Q3 revenue at $266,000, reflecting early-stage commercialization progress

* Net loss for Q3 2025 was $2.9 mln, compared to $2.5 mln in Q3 2024

* Company expects revenue growth in 2026 to offset cash burn

Outlook

* RenovoRx ( RNXT ) expects revenue growth in 2026 to offset cash burn

* RenovoRx ( RNXT ) plans strategic expansion with increased physician advocacy

Result Drivers

* COMMERCIAL EXPANSION - RenovoRx ( RNXT ) expanded from 5 to 14 cancer centers approved to purchase RenovoCath, reflecting growing market adoption

* SALES TEAM GROWTH - Co hired new sales leadership, including Philip Stocton as Senior Director of Sales, to support commercialization

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$2.91

Income mln

Q3 Basic -$0.08

EPS

Q3 $3.41

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for RenovoRx Inc ( RNXT ) is $3.75, about 73.3% above its November 12 closing price of $1.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)